{"id":70571,"date":"2026-07-24T18:34:06","date_gmt":"2026-07-24T10:34:06","guid":{"rendered":"https:\/\/flcube.com\/?p=70571"},"modified":"2026-07-24T18:34:07","modified_gmt":"2026-07-24T10:34:07","slug":"astrazenecas-etcamah-wins-eu-approval-for-esr1-mutated-breast-cancer-next-gen-serd-shows-56-risk-reduction-in-pivotal-trial","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=70571","title":{"rendered":"AstraZeneca&#8217;s Etcamah Wins EU Approval for ESR1-Mutated Breast Cancer \u2013 Next-Gen SERD Shows 56% Risk Reduction in Pivotal Trial"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>AstraZeneca plc<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/beta\/quote\/AZN:NYSE\">NYSE: AZN<\/a>) announced that the <strong>European Union<\/strong> has granted marketing authorization for <strong>Etcamah (camizestrant)<\/strong> in combination with a cyclin-dependent kinase (CDK) 4\/6 inhibitor for the treatment of adult patients with <strong>estrogen receptor (ER)-positive, HER2-negative locally advanced or metastatic breast cancer<\/strong> who have tested positive for <strong>ESR1 mutations<\/strong> and have not experienced disease progression during first-line endocrine therapy with a CDK4\/6 inhibitor.<\/p>\n\n\n\n<h2 id=\"h-regulatory-milestone\" class=\"wp-block-heading\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Agency<\/strong><\/td><td>European Medicines Agency (EMA)<\/td><\/tr><tr><td><strong>Approval Type<\/strong><\/td><td>Full marketing authorization<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>Etcamah (camizestrant) + CDK4\/6 inhibitor (palbociclib, ribociclib, or abemaciclib)<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>ER-positive, HER2-negative locally advanced or metastatic breast cancer with ESR1 mutation in patients without progression on 1st-line CDK4\/6 inhibitor therapy<\/td><\/tr><tr><td><strong>Approval Date<\/strong><\/td><td>23 Jul 2026<\/td><\/tr><tr><td><strong>Next Steps<\/strong><\/td><td>Commercial launch across EU member states<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-drug-profile-amp-mechanism-of-action\" class=\"wp-block-heading\">Drug Profile &amp; Mechanism of Action<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Molecule:<\/strong> Next-generation oral selective estrogen receptor degrader (SERD) and complete estrogen receptor antagonist<\/li>\n\n\n\n<li><strong>Target:<\/strong> Estrogen receptor with enhanced degradation capabilities compared to first-generation SERDs<\/li>\n\n\n\n<li><strong>Innovation:<\/strong> Potent oral SERD designed specifically for patients with ESR1 mutations who have developed resistance to standard endocrine therapies<\/li>\n\n\n\n<li><strong>Intellectual Property:<\/strong> Global patents held by <strong>AstraZeneca<\/strong>, covering the camizestrant compound and therapeutic use in ESR1-mutated breast cancer<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-clinical-evidence-serena-6-phase-iii-trial\" class=\"wp-block-heading\">Clinical Evidence \u2013 SERENA-6 Phase III Trial<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Endpoint<\/th><th>Result (Etcamah + CDK4\/6i)<\/th><th>Comparator (AI + CDK4\/6i)<\/th><th>Relative Benefit<\/th><\/tr><\/thead><tbody><tr><td><strong>Progression-Free Survival (PFS)<\/strong><\/td><td>Median 16.0 months<\/td><td>Median 9.2 months<\/td><td><strong>74% improvement<\/strong><\/td><\/tr><tr><td><strong>Risk Reduction (Progression\/Death)<\/strong><\/td><td>HR 0.44<\/td><td>Reference<\/td><td><strong>56% reduction<\/strong><\/td><\/tr><tr><td><strong>Statistical Significance<\/strong><\/td><td>95% CI: 0.31-0.60<\/td><td>\u2013<\/td><td><strong>p&lt;0.00001<\/strong><\/td><\/tr><tr><td><strong>Safety<\/strong><\/td><td>Consistent with known profiles of SERDs and CDK4\/6 inhibitors<\/td><td>\u2013<\/td><td>Manageable toxicity<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">The pivotal SERENA-6 trial demonstrated unprecedented efficacy in this molecularly defined patient population, meeting its primary endpoint with high statistical significance in a planned interim analysis.<\/p>\n\n\n\n<h2 id=\"h-market-impact-amp-outlook\" class=\"wp-block-heading\">Market Impact &amp; Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>EU Breast Cancer Landscape:<\/strong> Approximately 30-40% of ER-positive metastatic breast cancer patients develop ESR1 mutations after initial endocrine therapy, representing a significant unmet need<\/li>\n\n\n\n<li><strong>Revenue Forecast:<\/strong> Analysts project peak annual sales of <strong>$1.8-2.2 billion<\/strong> globally, with EU representing approximately 30% of the addressable market<\/li>\n\n\n\n<li><strong>Competitive Edge:<\/strong> As the first SERD approved specifically for ESR1-mutated breast cancer in the EU, Etcamah establishes a new standard of care in this precision oncology segment<\/li>\n\n\n\n<li><strong>Strategic Positioning:<\/strong> AstraZeneca plans coordinated launches across major EU markets with companion diagnostic partnerships to identify eligible ESR1-mutated patients<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding regulatory approvals, clinical outcomes, and commercial expectations for Etcamah. Actual results may differ due to risks including market adoption, reimbursement decisions, and competitive dynamics.<a href=\"https:\/\/flcube.com\/\"><a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>AstraZeneca plc (NYSE: AZN) announced that the European Union has granted marketing authorization for Etcamah&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,11],"tags":[130,15],"class_list":["post-70571","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-astrazeneca","tag-product-approvals"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.1) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>AstraZeneca&#039;s Etcamah Wins EU Approval for ESR1-Mutated Breast Cancer \u2013 Next-Gen SERD Shows 56% Risk Reduction in Pivotal Trial - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"AstraZeneca plc (NYSE: AZN) announced that the European Union has granted marketing authorization for Etcamah (camizestrant) in combination with a cyclin-dependent kinase (CDK) 4\/6 inhibitor for the treatment of adult patients with estrogen receptor (ER)-positive, HER2-negative locally advanced or metastatic breast cancer who have tested positive for ESR1 mutations and have not experienced disease progression during first-line endocrine therapy with a CDK4\/6 inhibitor.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=70571\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"AstraZeneca&#039;s Etcamah Wins EU Approval for ESR1-Mutated Breast Cancer \u2013 Next-Gen SERD Shows 56% Risk Reduction in Pivotal Trial\" \/>\n<meta property=\"og:description\" content=\"AstraZeneca plc (NYSE: AZN) announced that the European Union has granted marketing authorization for Etcamah (camizestrant) in combination with a cyclin-dependent kinase (CDK) 4\/6 inhibitor for the treatment of adult patients with estrogen receptor (ER)-positive, HER2-negative locally advanced or metastatic breast cancer who have tested positive for ESR1 mutations and have not experienced disease progression during first-line endocrine therapy with a CDK4\/6 inhibitor.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=70571\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-07-24T10:34:06+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-07-24T10:34:07+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70571#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70571\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"AstraZeneca&#8217;s Etcamah Wins EU Approval for ESR1-Mutated Breast Cancer \u2013 Next-Gen SERD Shows 56% Risk Reduction in Pivotal Trial\",\"datePublished\":\"2026-07-24T10:34:06+00:00\",\"dateModified\":\"2026-07-24T10:34:07+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70571\"},\"wordCount\":415,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"AstraZeneca\",\"Product approvals\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=70571#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70571\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=70571\",\"name\":\"AstraZeneca's Etcamah Wins EU Approval for ESR1-Mutated Breast Cancer \u2013 Next-Gen SERD Shows 56% Risk Reduction in Pivotal Trial - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-07-24T10:34:06+00:00\",\"dateModified\":\"2026-07-24T10:34:07+00:00\",\"description\":\"AstraZeneca plc (NYSE: AZN) announced that the European Union has granted marketing authorization for Etcamah (camizestrant) in combination with a cyclin-dependent kinase (CDK) 4\\\/6 inhibitor for the treatment of adult patients with estrogen receptor (ER)-positive, HER2-negative locally advanced or metastatic breast cancer who have tested positive for ESR1 mutations and have not experienced disease progression during first-line endocrine therapy with a CDK4\\\/6 inhibitor.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70571#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=70571\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70571#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"AstraZeneca&#8217;s Etcamah Wins EU Approval for ESR1-Mutated Breast Cancer \u2013 Next-Gen SERD Shows 56% Risk Reduction in Pivotal Trial\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"AstraZeneca's Etcamah Wins EU Approval for ESR1-Mutated Breast Cancer \u2013 Next-Gen SERD Shows 56% Risk Reduction in Pivotal Trial - Insight, China&#039;s Pharmaceutical Industry","description":"AstraZeneca plc (NYSE: AZN) announced that the European Union has granted marketing authorization for Etcamah (camizestrant) in combination with a cyclin-dependent kinase (CDK) 4\/6 inhibitor for the treatment of adult patients with estrogen receptor (ER)-positive, HER2-negative locally advanced or metastatic breast cancer who have tested positive for ESR1 mutations and have not experienced disease progression during first-line endocrine therapy with a CDK4\/6 inhibitor.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=70571","og_locale":"en_US","og_type":"article","og_title":"AstraZeneca's Etcamah Wins EU Approval for ESR1-Mutated Breast Cancer \u2013 Next-Gen SERD Shows 56% Risk Reduction in Pivotal Trial","og_description":"AstraZeneca plc (NYSE: AZN) announced that the European Union has granted marketing authorization for Etcamah (camizestrant) in combination with a cyclin-dependent kinase (CDK) 4\/6 inhibitor for the treatment of adult patients with estrogen receptor (ER)-positive, HER2-negative locally advanced or metastatic breast cancer who have tested positive for ESR1 mutations and have not experienced disease progression during first-line endocrine therapy with a CDK4\/6 inhibitor.","og_url":"https:\/\/flcube.com\/?p=70571","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-07-24T10:34:06+00:00","article_modified_time":"2026-07-24T10:34:07+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=70571#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=70571"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"AstraZeneca&#8217;s Etcamah Wins EU Approval for ESR1-Mutated Breast Cancer \u2013 Next-Gen SERD Shows 56% Risk Reduction in Pivotal Trial","datePublished":"2026-07-24T10:34:06+00:00","dateModified":"2026-07-24T10:34:07+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=70571"},"wordCount":415,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["AstraZeneca","Product approvals"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=70571#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=70571","url":"https:\/\/flcube.com\/?p=70571","name":"AstraZeneca's Etcamah Wins EU Approval for ESR1-Mutated Breast Cancer \u2013 Next-Gen SERD Shows 56% Risk Reduction in Pivotal Trial - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-07-24T10:34:06+00:00","dateModified":"2026-07-24T10:34:07+00:00","description":"AstraZeneca plc (NYSE: AZN) announced that the European Union has granted marketing authorization for Etcamah (camizestrant) in combination with a cyclin-dependent kinase (CDK) 4\/6 inhibitor for the treatment of adult patients with estrogen receptor (ER)-positive, HER2-negative locally advanced or metastatic breast cancer who have tested positive for ESR1 mutations and have not experienced disease progression during first-line endocrine therapy with a CDK4\/6 inhibitor.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=70571#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=70571"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=70571#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"AstraZeneca&#8217;s Etcamah Wins EU Approval for ESR1-Mutated Breast Cancer \u2013 Next-Gen SERD Shows 56% Risk Reduction in Pivotal Trial"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/70571","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=70571"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/70571\/revisions"}],"predecessor-version":[{"id":70574,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/70571\/revisions\/70574"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=70571"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=70571"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=70571"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}